Physician profile
Helen Brown
NPI 1457449548
$2,315.99
in general payments reported to CMS, 2019-2025
28 companies · $613 in 2025
The $613 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $87.17 · 2021: $275 · 2022: $288 · 2023: $453 · 2024: $284 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $515.57 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $389.17 | 2019-2023 | Lo Loestrin Fe, Orilissa, Qulipta |
| Pfizer INC. | $226.12 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.98 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $157.80 | 2024-2025 | |
| Daiichi Sankyo INC. | $127.17 | 2019-2023 | Injectafer |
| Exeltis, USA INC. | $91.54 | 2021-2025 | Slynd |
| Organon LLC | $84.07 | 2024-2025 | Nexplanon |
| Amgen INC. | $80.27 | 2020-2024 | Prolia, Evenity |
| Therapeuticsmd, INC. | $72.63 | 2019-2022 | |
| Optumhealth Care Solutions, LLC | $59.77 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Roche Diagnostics Corporation | $40.62 | 2019 | |
| Aspira Women'S Health INC | $28.32 | 2023-2024 | Ova1 |
| Lupin INC. | $27.53 | 2019 | |
| Avion Pharmaceuticals | $25.37 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $24.65 | 2019 | |
| Millicent US INC | $18.98 | 2025 | Intrarosa, Femlyv |
| Agile Therapeutics, INC. | $17.65 | 2021 | |
| Evofem Biosciences, INC. | $17.23 | 2021 | |
| Avanos Medical | $16.98 | 2021 | |
| Hologic Sales and Service, LLC | $16.57 | 2024 | Novasure, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $16.48 | 2023 | Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $16.25 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $16.25 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $15.18 | 2023 | Gardasil 9 |
| Innovation Technologies INC | $14.71 | 2025 | Irrisept |
| Covidien Lp | $14.14 | 2020 | |
| Meditrina | $13.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.